U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07560215) titled 'PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort' on April 24.
Brief Summary: PROMET-BR is an observational, retrospective and prospective real-world study in Brazil designed to characterize clinically relevant molecular alterations in metastatic prostate cancer and explore their association with patient outcomes in routine practice. The study will be conducted within Oncoclinicas & Co and will integrate centralized biomarker testing performed at OC Precision Medicine laboratories with retrospectively assembled clinical data from electronic health records (EHRs) from participating sites. Treatments are...